Is TB-500 safe for dogs?
The short answer
TB-500 is generally well tolerated in the veterinary literature, with injection-site swelling the most common observation. The decisive safety question is not tolerance but cancer status: because the compound is associated with promoting new blood vessel growth and cell migration, it is contraindicated in dogs with active or suspected malignancy. Screening before starting is not optional. It is also banned in competitive racing and is detectable on testing.
The critical risks
⚠ Contraindicated with active cancer
TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered.
Additional cautions
Banned in competitive racing
TB-500 is a prohibited substance in racing and is detectable in urine and plasma. Do not administer to any dog competing under an anti-doping authority.
What the evidence base actually is
Safety claims are only as good as the studies behind them.
TB-500 is a synthetic fragment of thymosin beta-4, a protein found naturally throughout the body and concentrated at wound sites. The active portion binds actin, the structural protein cells use to move. Research describes this helping repair cells migrate into damaged tissue, alongside new blood vessel formation and collagen laydown.
Dosing context
Safety is dose-dependent. These are the figures reported in the source literature.
Small / toy breed
under 22 lb (10 kg)
- Reported dose
- 0.2–2.5 mg per week
- Frequency
- Weekly TOTAL — split into 1-2 injections/week for a 2-4 week loading phase, then about half that weekly total for maintenance
- Duration
- Loading 2-4 weeks, maintenance 4-8 weeks
- Studied for
- Soft tissue injury, wound healing
Medium breed
22–77 lb (10–35 kg)
- Reported dose
- 1–8.75 mg per week
- Frequency
- Weekly TOTAL — split into 1-2 injections/week for a 2-4 week loading phase, then about half that weekly total for maintenance
- Duration
- Loading 2-4 weeks, maintenance 4-8 weeks
- Studied for
- Tendon and ligament injury, mobility, post-surgical recovery
Large / giant breed
over 77 lb (35 kg)
- Reported dose
- 3.5–15 mg per week
- Frequency
- Weekly TOTAL — split into 1-2 injections/week for a 2-4 week loading phase, then about half that weekly total for maintenance
- Duration
- Loading 2-4 weeks, maintenance 4-8 weeks
- Studied for
- Orthopaedic injury, chronic joint disease
See the full TB-500 profile for mechanism, protocol and monitoring detail.
Common questions
Is TB-500 safe for dogs?+
TB-500 is generally well tolerated in the veterinary literature, with injection-site swelling the most common observation. The decisive safety question is not tolerance but cancer status: because the compound is associated with promoting new blood vessel growth and cell migration, it is contraindicated in dogs with active or suspected malignancy. Screening before starting is not optional. It is also banned in competitive racing and is detectable on testing.
What are the side effects of TB-500 in dogs?+
Contraindicated with active cancer: TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered. Banned in competitive racing: TB-500 is a prohibited substance in racing and is detectable in urine and plasma. Do not administer to any dog competing under an anti-doping authority.
Can TB-500 be given to a dog with cancer?+
No. TB-500 is contraindicated in dogs with active or suspected cancer. TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered.
Does my dog need testing before starting TB-500?+
No compound-specific genetic testing is established for TB-500. Baseline bloodwork before starting, and repeat testing during a protocol, is standard practice and lets your veterinarian catch a problem before it becomes clinically apparent.
References
- 1.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
- 2.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 3.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 4.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
- 5.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.